Literature DB >> 1596885

Placental transfer of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone instilled intratracheally in Syrian golden hamsters.

R Jorquera1, A Castonguay, H M Schuller.   

Abstract

The tobacco-specific N-nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone (NNK) is a potent tumorigen in adult Syrian golden hamsters and an active transplacental carcinogen in this species. In this study, we have investigated the biodistribution and metabolism of NNK in maternal and fetal hamster tissues as a function of the dose and the time after NNK treatment. Hamsters on day 15 of gestation were instilled intratracheally with single doses (0.05-100 mg/kg) of [5-3H]NNK and sacrificed 30 min later or treated with a single dose (25 mg/kg) of [5-3H]NNK and sacrificed at various times (5-360 min) after treatment. Total radioactivity was quantified in maternal tissues (liver, lung, kidney, placenta, and stomach), in whole fetus and in fetal tissues (liver and lung). NNK and its metabolites were extracted from selected tissues (maternal plasma, amniotic fluid, fetal liver, and lung) and assayed by high-performance liquid chromatography-scintigraphy. Thirty min after treatment, radioactivity associated with NNK and its metabolites showed similar widespread tissue distribution patterns at all doses, with a linear dose relationship observed in whole fetus and fetal tissues. NNK levels detected in maternal plasma, amniotic fluid, fetal liver, and lung were also related linearly to dose. At high doses (25 mg/kg or more) of NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol was the major metabolite detected in maternal plasma. Pyridine N-oxidation of NNK predominated at the lowest doses (0.05 and 0.5 mg NNK/kg). The toxicokinetics of NNK demonstrated that this carcinogen is rapidly absorbed from the maternal lung (less than 5 min), metabolized mainly to 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanol, and quickly distributed into the maternal-fetal compartment. Both NNK and its main metabolite 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanol were eliminated slowly from the amniotic fluid, with levels still detectable up to 6 h after NNK treatment. These results demonstrated that NNK instilled intratracheally in pregnant hamsters crossed the placental barrier even at low doses. Moreover, NNK quickly reached fetal tissues and amniotic fluid and was eliminated slowly from these tissues, resulting in an extended exposure of the fetus to this tobacco-specific carcinogen.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1596885

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Nitrosatable drug exposure during the first trimester of pregnancy and selected congenital malformations.

Authors:  Jean D Brender; Martha M Werler; Mayura U Shinde; Ann M Vuong; Katherine E Kelley; John C Huber; Joseph R Sharkey; John S Griesenbeck; Paul A Romitti; Sadia Malik; Lucina Suarez; Peter H Langlois; Mark A Canfield
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2012-08-18

2.  Transplacental carcinogenicity of low doses of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone administered subcutaneously or intratracheally to hamsters.

Authors:  H M Schüller; R Jorquera; X Lu; A Riechert; A Castonguay
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

3.  Maternal dietary intake of nitrates, nitrites and nitrosamines and selected birth defects in offspring: a case-control study.

Authors:  John C Huber; Jean D Brender; Qi Zheng; Joseph R Sharkey; Ann M Vuong; Mayura U Shinde; John S Griesenbeck; Lucina Suarez; Peter H Langlois; Mark A Canfield; Paul A Romitti; Peter J Weyer
Journal:  Nutr J       Date:  2013-03-21       Impact factor: 3.271

4.  Agonist and antagonist effects of tobacco-related nitrosamines on human α4β2 nicotinic acetylcholine receptors.

Authors:  Simone Brusco; Paola Ambrosi; Simone Meneghini; Andrea Becchetti
Journal:  Front Pharmacol       Date:  2015-09-22       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.